ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Insulin Glargine

Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.

Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 9, 2005184 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only1241 open or runningphase 4since Sep 9, 2005Sep 30, 2002none ahead
Novo Nordiskits history only280 open or runningphase 4since Sep 12, 2005Oct 29, 2004none ahead
Eli Lilly250 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Diabetes Care Centerits history only20 open or runningno phasesince Apr 3, 2007Apr 3, 2007none ahead
Biodelits history only10 open or runningphase 2since Oct 21, 2009Oct 21, 2009none ahead
Geropharmits history only10 open or runningno phasesince Sep 23, 2019Sep 23, 2019none ahead
ikfe-CROits history only10 open or runningphase 4since Dec 5, 2011Dec 5, 2011none ahead
Profil Institut für Stoffwechselforschungits history only10 open or runningphase 1since Sep 3, 2009Sep 3, 2009none ahead
Wockhardtits history only10 open or runningphase 1since May 12, 2011May 12, 2011none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Sep 12, 2005.

  1. Aug 19, 20112 phase 3 studiesNCT01421459, NCT01421147
  2. Oct 5, 2011Phase 1 study in Diabetes MellitusNCT01476345 · 80 enrolled · South Africa
  3. May 15, 2012Phase 1 study in Diabetes Mellitus, Type 1NCT01600950 · 20 enrolled · Germany
  4. Jul 2, 2012Phase 1 study in Healthy VolunteersNCT01634165 · 24 enrolled · Singapore
  5. Sep 17, 2012Phase 1 study in HealthyNCT01688635 · 91 enrolled · Singapore
  6. May 5, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02132637 · 68 enrolled · United States, Germany
  7. Nov 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02302716 · 493 enrolled · United States, India, Korea, Republic of and more
  8. Nov 3, 2016Phase 1 study in HealthyNCT02955953 · 127 enrolled · Singapore
  9. Nov 7, 20172 phase 3 studiesNCT03338023, NCT03338010
  10. Jun 1, 2018Phase 1 study in HealthyNCT03555305 · 58 enrolled · China
  11. Nov 5, 2019Phase 4 study in Diabetes Mellitus, Type 2NCT04153981 · 304 enrolled · India
  12. Jul 10, 2020No phase study in Diabetes Mellitus, Type 1NCT04484779 · 67 enrolled · United States
  13. Apr 27, 2021Phase 4 study in Diabetes Mellitus, Type 2NCT04864977 · United States
  14. Jul 14, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05462756 · 730 enrolled · United States, Argentina, Germany and more

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 25 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05462756Diabetes Mellitus, Type 2 · United States, Argentina, Germany and more3CompletedFeb 27, 2024730
NCT04864977Diabetes Mellitus, Type 2 · United States4WithdrawnJun 6, 20220
NCT04484779Diabetes Mellitus, Type 1 · United States–CompletedDec 22, 202067
NCT04153981Diabetes Mellitus, Type 2 · India4CompletedJul 30, 2021304
NCT03555305Healthy · China1CompletedNov 4, 201958
NCT03338023Diabetes Mellitus, Type 1 · China3CompletedMar 5, 2020272
NCT03338010Diabetes Mellitus, Type 2 · China3CompletedMar 18, 2020536
NCT02955953Healthy · Singapore1CompletedJan 4, 2017127
NCT02302716Diabetes Mellitus, Type 2 · United States, India, Korea, Republic of and more3CompletedJul 2016493
NCT02132637Diabetes Mellitus, Type 2 · United States, Germany3CompletedJul 201568
NCT01688635Healthy · Singapore1CompletedFeb 201391
NCT01634165Healthy Volunteers · Singapore1CompletedSep 201224
NCT01600950Diabetes Mellitus, Type 1 · Germany1CompletedJul 201220
NCT01476345Diabetes Mellitus · South Africa1CompletedJul 201280
NCT01421459Diabetes Mellitus, Type 2 · United States, Czech Republic, France and more3CompletedSep 2012759
NCT01421147Diabetes Mellitus, Type 1 · United States, Belgium, Germany and more3CompletedAug 2012536
NCT01374178Diabetes Mellitus · Singapore1CompletedJul 201116
NCT01136746Hyperglycemia · United States3TerminatedNov 201116
NCT00560417Diabetes Mellitus, Type 2 · United States, Puerto Rico3CompletedDec 2009339
NCT00551538Diabetes Mellitus, Type 2 · United States4Completed15
NCT00551356Diabetes Mellitus, Type 2 · Mexico3Completed53
NCT00437112Diabetes Mellitus, Type 2 · United States, Brazil, India and more3CompletedMay 2008142
NCT00355849Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more3CompletedJun 2008555
NCT00191464Diabetes Mellitus, Type 2 · United States, Australia, Greece and more4Completed320
NCT00191178Diabetes Mellitus, Type 2 · United States4Completed60

How it is read

Names in the registry

  • “insulin glargine”, 38 entries
  • “Insulin Glargine”, 27 entries
  • “Insulin glargine”, 20 entries
  • “INSULIN GLARGINE”, 15 entries
  • “LY2963016”, 11 entries

Codes read as this program: HOE901.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.